ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0193

Evaluation of electronic health record and efficiency tool utilization by pediatric subspecialists
Abstract Number: 0194

Evaluation of a Home-based Therapeutics Service: Feasibility, Patient and Caregiver Experience, and Cost
Abstract Number: 0195

Utility of Repeat ANA Testing
Abstract Number: 0196

Increasing Timely Rheumatology Evaluation for High Risk Lupus Patients
Abstract Number: 0197

Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
Abstract Number: 0198

Variation in RA disease activity measure assessment and treatment change documentation in virtual vs in-office rheumatology visits
Abstract Number: 0199

Pain Phenotypes and Social Determinants of Health in Chronic Chikungunya Arthritis: A Cross-Sectional Study
Abstract Number: 0200

Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
Abstract Number: 0201

Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
Abstract Number: 0202

Saudi Society for Rheumatology Consensus Recommendation on Vaccination Strategies in Adults Saudi with Autoimmune Rheumatic Disorders
Abstract Number: 0203

Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study
Abstract Number: 0204

Immunogenicity and safety summary for the chikungunya virus-like particle vaccine development programme
Abstract Number: 0205

Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Abstract Number: 0206

Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
Abstract Number: 0207

The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].